Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
Authors
Keywords
-
Journal
Obesity Reviews
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-02
DOI
10.1111/obr.13170
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
- (2020) John Sharretts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity: global epidemiology and pathogenesis
- (2019) Matthias Blüher Nature Reviews Endocrinology
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Guideline Recommendations for Obesity Management
- (2018) Donna H. Ryan et al. MEDICAL CLINICS OF NORTH AMERICA
- Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population
- (2018) Chia-Wen Lu et al. Obesity Research & Clinical Practice
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet
- (2017) Jena Shaw Tronieri et al. Obesity
- Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial
- (2016) Olivia M. Farr et al. DIABETES
- Weight regaining: From statistics and behaviors to physiology and metabolism
- (2015) Costas A. Anastasiou et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs
- (2013) E. W. Chan et al. Obesity Reviews
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure
- (2010) Corby K. Martin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women
- (2008) Steven R. Smith et al. Obesity
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started